Boillhealthcare (01246.HK) announced on July 2 that its revenue for the fiscal year ending March 31, 2024 was HKD 285 million, a decrease of 18.11% year-on-year; the company's shareholders' loss for the period was HKD 119 million, compared to a loss of HKD 428 million in the same period last year; basic loss per share was 8.74 Hong Kong cents.

The main reason for the decline in revenue is that there were no sales of building materials in the 2024 fiscal year, while the sales of building materials were about HKD 17.86 million. However, the property delivered by the Group's Yangzhong project increased from about HKD 169.5 million in the fiscal year of 2023 to HKD 285.0 million in the fiscal year of 2024.